We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced final data from the phase III study (INO-VATE ALL or Study 1022) on inotuzumab ozogamicin for the treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL).
The open-label, randomized study evaluated the safety and efficacy of the candidate, in comparison to investigator-choice chemotherapy, in adults (n=326) with relapsed or refractory CD22-positive ALL.
The study had two primary endpoints – complete response with or without hematologic remission and overall survival (OS). Data from the study revealed an improvement over chemotherapy on a number of measures that included complete hematologic remission and progression-free survival (PFS). The study met its first primary endpoint of complete response, but failed to reach statistical significance in its second primary endpoint. However, the second primary endpoint of OS demonstrated a strong trend toward longer OS.
Results were published in the The New England Journal of Medicine. Moreover, updated data on OS were presented at the annual meeting of the Congress of the European Hematology Association.
We note that inotuzumab ozogamicin has Breakthrough Therapy designation in the U.S. for ALL.
Moreover, Pfizer, with its partner Merck & Co. Inc. (MRK - Free Report) , announced results from two phase III studies (VERTIS Mono and VERTIS Factorial) on ertugliflozin for the treatment of patients with type II diabetes.
Ertugliflozin (5 mg and 15 mg daily) was evaluated as monotherapy in the VERTIS Mono study, while the VERTIS Factorial study evaluated the co-administration of the candidate with Merck’s diabetes drug, Januvia.
Results from the studies demonstrated statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested. Data were presented at the Scientific Sessions of the American Diabetes Association.
The companies have expanded the VERTIS CV study to enable testing for superiority in improving CV outcomes in patients with type II diabetes. They plan to submit New Drug Applications in the U.S. for ertugliflozin and the two fixed-dose combination tablets – ertugliflozin/Januvia, and ertugliflozin/metformin – by 2016 end.
Pfizer currently sports a Zacks Rank #1 (Strong Buy). Bristol-Myers Squibb Company (BMY - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) are two other favorably placed stocks in the health care sector, carrying the same Zacks Rank as Pfizer.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
Pfizer Inc. (PFE - Free Report) announced final data from the phase III study (INO-VATE ALL or Study 1022) on inotuzumab ozogamicin for the treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL).
The open-label, randomized study evaluated the safety and efficacy of the candidate, in comparison to investigator-choice chemotherapy, in adults (n=326) with relapsed or refractory CD22-positive ALL.
The study had two primary endpoints – complete response with or without hematologic remission and overall survival (OS). Data from the study revealed an improvement over chemotherapy on a number of measures that included complete hematologic remission and progression-free survival (PFS). The study met its first primary endpoint of complete response, but failed to reach statistical significance in its second primary endpoint. However, the second primary endpoint of OS demonstrated a strong trend toward longer OS.
Results were published in the The New England Journal of Medicine. Moreover, updated data on OS were presented at the annual meeting of the Congress of the European Hematology Association.
We note that inotuzumab ozogamicin has Breakthrough Therapy designation in the U.S. for ALL.
Moreover, Pfizer, with its partner Merck & Co. Inc. (MRK - Free Report) , announced results from two phase III studies (VERTIS Mono and VERTIS Factorial) on ertugliflozin for the treatment of patients with type II diabetes.
Ertugliflozin (5 mg and 15 mg daily) was evaluated as monotherapy in the VERTIS Mono study, while the VERTIS Factorial study evaluated the co-administration of the candidate with Merck’s diabetes drug, Januvia.
Results from the studies demonstrated statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested. Data were presented at the Scientific Sessions of the American Diabetes Association.
The companies have expanded the VERTIS CV study to enable testing for superiority in improving CV outcomes in patients with type II diabetes. They plan to submit New Drug Applications in the U.S. for ertugliflozin and the two fixed-dose combination tablets – ertugliflozin/Januvia, and ertugliflozin/metformin – by 2016 end.
Pfizer currently sports a Zacks Rank #1 (Strong Buy). Bristol-Myers Squibb Company (BMY - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) are two other favorably placed stocks in the health care sector, carrying the same Zacks Rank as Pfizer.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>